All patients with an intravascular device in the intensive care units at Prince of Wales and Prince Henry Hospitals between July and September 1995 were followed for the development of line-related bacteraemia per 1000 line days. Cases of sepsis related to an intravascular device were identified using a case definition which incorporated clinical and laboratory parameters. Data were collected prospectively for the dates of insertion and removal of devices for 188 lines inserted in 69 patients. The majority (90%) of lines had both date of insertion and removal documented allowing the calculation of the rate of primary bacteraemia over 832 at-risk line days. Multiple concurrent lines were more common (88.4%) than single lines, with one central and one or two peripheral lines being the most common (42.3%) combination. Five cases of bacteraemia were diagnosed clinically and confirmed microbiologically. The incidence density of primary bacteraemia was 6.0 per 1000 line days (CI 95% 5.7-6.3).
Currently, rates of nosocomial bacteraemia collected by hospitals participating in the Australian Council on Healthcare Standards (ACHS) accreditation process are reported as a hospital-wide clinical indicator of quality of care in its Care Evaluation Program (CEP). The definition for this rate is provided by the ACHS and includes all admissions of greater than 48 hours duration as a denominator and all hospital-acquired bacteraemia cases as the numerator. The number of patients investigated by blood culture may be used as an alternative denominator 1 . As hospitals move towards casemix funding and provide funders with measures of performance, it is imperative that the measure of hospital-wide nosocomial bacteraemia is valid. The present denominator required by the ACHS to measure nosocomial bacteraemia is fluid and it does not reflect quality care or breaches in quality care because patients not at-risk of a nosocomial bacteraemia are included in the denominator. Intravascular devices are the most common primary source of nosocomial bacteraemia and therefore identify the population at risk [4] [5] [6] [7] .
Difficulties in calculating reliable device-related bacteraemia rates have resulted in numerous proxy measures for the populations at risk [5] [6] [7] [8] , such as: • a percentage of all bacteraemia and fungaemia episodes 5 , • the number of device-related episodes of septicaemia/bacteraemia as a percentage of all laboratory proven nosocomial septicaemia 6 , • episodes of bacteraemia per 1000 patient discharges 7 , • percentages of all patients administered total parenteral nutrition 8 . Each of these methods has attempted to quantify the risk to a group of patients with an intravascular device (IVD). Rates derived from such methods can not be compared because the denominators and risk factors are different 6 . Moreover, these rates do not indicate the risk of bacteraemia for a patient with more than one line in situ, concurrently or consecutively.
The device-related bacteraemia rate developed by the National Nosocomial Infection Surveillance (NNIS) System 3 in the United States can be adopted to provide an epidemiologically sound outcome indicator. One barrier to its implementation is the lack of routine documentation of the insertion and removal dates of intravascular devices in Australian hospitals. This paper describes the development of a method of measuring IVD-related bacteraemia that includes only patients at risk of developing a primary nosocomial bacteraemia. This is achieved by documenting line days and identifying cases of bacteraemia according to NNIS guidelines.
METHODS
The device-related bacteraemia indicator was developed in two intensive care units at two large public metropolitan university teaching hospitals following ethics committee approval. Data collection was undertaken from July 17, 1995 to September 30, 1995.
Definitions

Eligible Patients
All adult intensive care unit (ICU) patients, with at least one central or peripheral line were followed prospectively. Data collection began with the insertion of the device in the ICU or the admission of a patient to the ICU with a device in situ. Active data collection ceased for each patient with the removal of the last device, when the patient was transferred to another health care facility or died. Each patient with any intravascular device in situ was monitored for the duration of their ICU stay. Patients developing microbiologically confirmed bacteraemia within 48 hours of discharge from ICU with lines in situ were reviewed for inclusion as ICU cases of primary bacteraemia.
Case Definition
In accordance with the NNIS 3 nosocomially acquired device-related bacteraemia occurred when: a) Microbiologically confirmed bloodstream infection met one of the following criteria: 1. Recognized pathogen isolated from blood culture and pathogen is not related to infection at another site. 2. One of the following: fever (>38°C), rigors, or hypotension and any of the following: i. Common skin contaminant isolated from two blood cultures drawn on separate occasions and organism is not related to infection at another site. ii. Common skin contaminant isolated from blood culture from patient with intravascular access device and physician institutes appropriate antimicrobial therapy. iii. Positive antigen test on blood and organism is not related to infection at another site. b) Clinical sepsis met either of the following criteria:
One of the following clinical signs or symptoms with no other recognized cause: fever (>38°C), hypotension (systolic pressure (90 mmHg), or oliguria (<20 ml/hr) and all of the following:
i. Blood culture not done or no organism or antigen detected in blood. ii. No apparent infection at another site. iii. Physician institutes appropriate antimicrobial therapy for sepsis.
Episodes of Care a) Total Line Days
Each admission to an intensive care unit (ICU) was treated as a separate episode. The total number of line days for each admission were counted. The incidence density of primary bacteraemia was a rate per 1000 line days.
b) At-Risk Line Days
Each line in eligible patients contributed to the total line days. The time, calculated in days, between the reported date of each device being inserted and the date of removal was the cumulative number of line days. No statistical correction was applied for multi-lumen lines. The daily usage of each lumen of multi-lumen catheters and the nature of the intravenous fluid administered were not recorded.
Primary Bacteraemia Rate
The numerator: all eligible patients diagnosed with a primary bacteraemia who fulfilled the NNIS criteria for bacteraemia. Organisms of the same genus and species, and antibiotic susceptibility profile which contained no more than two differences were considered the same strain and therefore part of the same episode.
The denominator: all at-risk line days were summed. When a patient was diagnosed with a nosocomial primary bacteraemia infection they continued to contribute at-risk patient-days.
Collection Procedure of Incidence Density Data
Data for patients with a device in situ included: 
Reliability of Data
Each case of laboratory-proven bacteraemia was confirmed for accuracy in recording by reference to the patient's medical record. Each case where bacteraemia was diagnosed clinically and without laboratory confirmation was checked for evidence of agreement with the NNIS definition 3 . Any survey report of a peripheral line in situ for a prolonged period 9 was checked for documentation of the date of insertion and date of removal.
Analysis
Data were examined for the dates of insertion and removal of IVD and total number of line days by central and peripheral lines. Only patients with a recorded date of insertion and removal for each IVD were included in the analysis. The rate of bacteraemia and 95% confidence intervals were calculated per 1000 line days. In situ line days were examined for the range, median, lower (LQ) and upper quartiles (UQ). Combinations of IVD were examined by type of combination and the number of days a patient was exposed to a particular combination (occasion) to establish patterns of IVD utilization.
RESULTS
Documentation
During 76 survey days a total of 188 lines were inserted into 69 patients in the intensive care units. Of these devices, 169 (90%) in 58 eligible patients had the date of insertion and removal documented. APACHE II and III scores were documented in 39 (67.2%) eligible patients. The APACHE II scores ranged from 4 to 40 (median 17) while the APACHE III scores ranged from 16 to 170 (median 66).
Total IVDs In Situ
Fifty-eight (58/69) eligible intensive care patients had 169 lines in situ for a cumulative 832 line days. During the survey period, 56% of lines were central lines and 44% were peripheral lines ( Table 1 ). Site of insertion or type of line was documented for 83% of lines. The insertion site of all peripheral lines and 70% (67/95) of all central lines was recorded. Of the central lines with insertion site specified, 70.5% (47/67) were pulmonary artery lines. Central lines were in situ for a median of six days (range 1-30; LQ 5, UQ 11). Of the peripheral lines, arterial lines were the most common (33%, 24/74) and were in situ for a median of two days (range 1-42; LQ 5, UQ 14).
Peripheral venous lines were used in 9.9% of cases for between 24 hours to eight days with 21% in situ for more than 48 hours.
Combinations of Concurrent IVD
Seventy-one per cent (40/58) of patients had 165 IVDs in situ concurrently for 74% (614/832) of the total line days for the study group. Multiple IVDs were in situ from 1 to 52 days (median 2; LQ 1, UQ 4). One central line in combination with one or two concurrent peripheral lines were in situ for a total of 420 line days. This combination was in situ from 1 to 52 days (median 3; LQ 1, UQ 8). Combinations of two central and between one and three concurrent peripheral lines were in situ for a total of 121 line days. Patients with this combination had lines in situ from 1 to 11 days (median 1; LQ 1, UQ 4).
Cases of Bacteraemia
Five cases of primary bacteraemia were identified during the 832 at-risk line days or 6.0 bacteraemia infections per 1000 line days ( Table 2 ). All cases were microbiologically confirmed. Two cases were due to aerobic gram-negative bacilli and three cases were aerobic gram-positive cocci. No fungaemic episodes due to line sepsis were identified. The five cases of bacteraemia occurred in patients with a median of two concurrent lines at the time of bacteraemia being diagnosed, usually with one central and one peripheral line in combination. Primary bacteraemia was diagnosed after a median of 18 line days (range 2 to 27 days).
Clinical records were compared with the laboratory results for nine cases of microbiologically confirmed bacteraemia. Data for five cases were found to be accurate and four were assessed as secondary bacteraemia as clinical diagnosis was inconsistent with NNIS definition of bacteraemia. Microbiologically confirmed cases during the study period were also documented clinically by intensivists.
DISCUSSION
The aim of our project was to re-evaluate the method of measurement of the primary bacteraemia rate irrespective of line type. This study successfully captured insertion and removal dates of peripheral and central catheters, and tracked the number and type of lines in situ at any given time. The ACHS clinical outcome indicators have encouraged hospitals to measure clinical care; however, the lack of epidemiological rigour in these measures does not allow clinicians to intervene with any degree of certainty 10 . Our measurement of the rate of nosocomial bacteraemia differed from that of ACHS on several important epidemiological principles, population bias, validity, reliability and measurement bias 11 .
Population Bias. The population we measured (denominator) had the potential to become infected with a device-related bacteraemia (numerator) unlike the ACHS denominator which would bias the outcome towards zero. The ACHS include all admissions for more than 48 hours, such as psychiatric patients, geriatric and rehabilitation patients who are not at risk of the outcome 1 . The alternative ACHS laboratory population 1 , the number of patients investigated by blood culture, excludes patients at risk who did not have laboratory investigated or diagnosed infection. We chose the ICU as a study population because we believed patients were at high risk of having at least one IVD in situ, and the methodology was feasible for other ICUs and wards with at-risk patients to apply. Other hospital populations where a high volume of insertion of IVD occur are Emergency Department and Operating Theatres. However, tracking the movement of these patients is laborious and requesting documentation of insertion details in emergency situations is impractical.
We recognize that our rate of bacteraemia could be somewhat biased because of the inclusion of pulmonary artery and peripheral arterial lines used for monitoring patients rather than treatment. Nevertheless, these lines were included because they provide a portal of entry and a potential source of bacteraemia. In future we would hope that ICUs collaborate to measure primary bacteraemia so that outcome may be stratified by central and peripheral lines.
Validity and Reliability. The NNIS 3 definition of primary bacteraemia with additional criteria and prospective data collection is a step towards obtaining a valid measure of primary not secondary bacteraemia rate. This is essential to evaluate new devices and altered protocols for insertion, care, change and removal. The ACHS definition 1 of a bacteraemia would have high reliability because of the unambiguous definition. However, reliability is at the expense of validity because of the high possibility of including secondary bacteraemia.
Measurement Bias. Our measurement is not biased towards an over-or underestimation as the incidence density allowed patients with different risk periods, line days, to be included in the denominator. The ACHS calculation 1 assumes every patient is at risk for equal periods. In addition, incidence density also provides a concept of "speed" at which bacteraemia develops in a population.
The pathogenesis of a primary device-related bacteraemia is complex 4 and the proportion of infection due to extrinsic factors, such as catheter material, nursing management of the catheter and patient illness, may never have their effect truly adjusted. However, we believe improved surveillance of primary bacteraemia infections through improved documentation of the period of risk and standardized clinical diagnosis provides a key indicator to identify where IV therapy is a major risk for an adverse clinical outcome and cause of increased morbidity.
